



HHS Public Access

Author manuscript

Adv Chronic Kidney Dis. Author manuscript; available in PMC 2024 June 26.

Published in final edited form as:

Adv Chronic Kidney Dis. 2021 November ; 28(6): 517–527. doi:10.1053/j.ackd.2021.10.009.

A Cascade of Structural Barriers Contributing to Racial Kidney Transplant Inequities

Dinushika Mohottige,

Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC

Center for Community and Population Health Improvement, Clinical and Translational Science Institute, Duke University School of Medicine, Durham, NC

Lisa M. McElroy,

Division of Abdominal Transplant, Department of Surgery, Duke University School of Medicine, Durham, NC

Department of Population Health Sciences, Duke University School of Medicine, Durham, NC

L. Ebony Boulware

Center for Community and Population Health Improvement, Clinical and Translational Science Institute, Duke University School of Medicine, Durham, NC

Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC

Abstract

Stark racial disparities in access to and receipt of kidney transplantation, especially living donor and pre-emptive transplantation, have persisted despite decades of investigation and intervention. The causes of these disparities are complex, are inter-related, and result from a cascade of structural barriers to transplantation which disproportionately impact minoritized individuals and communities. Structural barriers contributing to racial transplant inequities have been acknowledged but are often not fully explored with regard to transplant equity. We describe longstanding racial disparities in transplantation, and we discuss contributing structural barriers which occur along the transplant pathway including pretransplant health care, evaluation, referral processes, and the evaluation of transplant candidates. We also consider the role of multilevel socio-contextual influences on these processes. We believe focused efforts which apply an equity lens to key transplant processes and systems are required to achieve greater structural competency and, ultimately, racial transplant equity.

Address correspondence to Dinushika Mohottige, MD, MPH, Duke University School of Medicine, 200 N. Morris Street, 3rdFloor, Durham, NC 27701. Dinushika.mohottige@duke.edu.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Keywords

Equity; Racial disparities; Structural competency; Pretransplant kidney care; Transplant referral; Transplant evaluation

RACIAL TRANSPLANT DISPARITIES IN THE UNITED STATES

Black Americans in the United States have a 4-fold higher risk of developing end-stage kidney disease than their White counterparts, yet they remain less likely to receive pre-emptive deceased donor and living donor kidney transplants.¹⁻⁴ Before the implementation of the 2014 revised kidney allocation system (KAS) which reduced inequities in waitlist time (based on dialysis vintage) and immunologic barriers (high panel reactive antibodies), significant racial disparities in the receipt of deceased donor kidney transplants (DDKTs) were intractable for decades.^{5,6} Although the KAS reduced disparities in DDKT recipients, racial and ethnic waitlist disparities persist despite interventions. For instance, in 2020, Black patients were less likely than White patients to be pre-emptively waitlisted for transplant (3.9% vs 5%) (United States Renal Data System),⁴ and rates of pre-emptive DDKT are worsening among Black compared with White individuals.^{1,7} This finding is notable^{8,9} because pre-emptive kidney transplantation confers the unique benefits of reducing time spent on dialysis, reduced dialysis-associated morbidity, inferior quality of life, and higher dialysis-related costs.¹⁰⁻¹³

In a study of pre-emptive transplantation before and after KAS, individuals with non-White race, younger age, male sex, lower educational attainment, and public primary insurance had lower odds of pre-emptive transplant after (versus before) KAS.⁷ Notably, racial disparities between Black and White individuals also widened by 21%, indicating the need for further identification and implementation of interventions to address root causes.⁷ Furthermore, racial disparities in living donor kidney transplantation, which confers superior outcomes for graft survival and morbidity when compared with all other transplants, have worsened over the last decade, whereby Black individuals have 73% lower hazard of receiving living donor kidney transplants than White individuals.^{14,15}

A CASCADE OF CONTRIBUTORS TO RACIAL DISPARITIES IN US KIDNEY TRANSPLANTS

Racial disparities in the receipt of kidney transplants stem from inequities which occur at several phases of the transplant journey, including during pretransplant kidney health and kidney care, referral for transplant, and completion of the transplant evaluation and waitlisting processes.^{1,14,16-18}

Pretransplant Health and Kidney Care

Racial differences in pretransplant health and kidney care may contribute to racial kidney transplant inequities.¹⁹⁻²¹ For instance, individuals with diabetes are less likely to be referred for pre-emptive transplant than their counter-parts.^{22,23} Because diabetes disproportionately burdens individuals who are Black, Hispanic-Latinx, Asian, and Native

American Pacific Islander when compared with White individuals, lower referrals to transplants among individuals with diabetes may disproportionately impact ethnic/racial minority individuals and contribute to racial kidney transplant inequities.²⁴

Timely recognition of CKD by patients and their clinicians is also important to ensure patients receive timely referrals for kidney transplants.^{25–28} Yet, numerous studies have demonstrated low patient awareness of kidney disease (7.8% among individuals with CKD risk factors)²⁵ and low perceived individual risk (26% among African Americans who had CKD and risk factors in a multistate survey).²⁹ Evidence also suggests racial minorities with CKD risk factors may be more unaware than others of their CKD risks or options for kidney care including transplant.^{30,31} Low CKD knowledge has been associated with low health literacy and may result from limited access to CKD education, among other factors (including low education level or poor access to health information sources such as the internet), which are structural and modifiable. Racial disparities in kidney disease awareness have also been a notable contributor to poor control of kidney-impacting comorbidities including diabetes and hypertension, which may negatively impact transplant evaluation and candidacy.^{23,32} Low CKD awareness is exacerbated by suboptimal adherence to recommended clinical testing for CKD diagnosis and management among internal medicine and family physicians,³³ as well as implicitly and explicitly biased interactions with patients that sometimes impair effective, equitable shared decision-making.^{34,35}

Racial differences in receipt of high-quality care including the diagnosis and treatment of hypertension³⁶ and diabetes^{37,38} may also contribute to transplant disparities. In primary care, physicians' discussions about CKD and risks among African Americans have been demonstrated to be suboptimal^{39,40} and noted to occur in few (26%) high-risk patient visits, even though some of these individuals may benefit from early transplant education.⁴⁰ In one study, Black race was associated with lower rates of sodium-glucose cotransporter-2 inhibitor use among Black individuals than others (odds ratio [OR] 0.83; 95% confidence interval [CI]: 0.81–0.85).⁴¹

Physicians' suboptimal adherence to pretransplant nephrology referral guidelines may also play a role in transplant inequities. Despite national recommendations to refer patients to nephrologists for patients with acute kidney injury, estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m², severe albuminuria, rapid GFR decline, hematuria, and/or CKD complications,²³ racial minorities are 33% less likely than others to receive timely nephrology care, a critical juncture before referral for transplantation.^{1,42–47} Other systemic health care practices, including the inclusion of a Black race coefficient used to estimate kidney function across the United States, may have contributed to ongoing racial inequities.^{48–51} Developed with the intent of enhancing the precision of prior kidney function estimating equations, this coefficient as used in the Chronic Kidney Disease Epidemiology Collaboration equation raises the estimated GFR for Black individuals by 16%.⁵² This adjustment systematically impacts individuals racialized as “Black” by delaying the time to transplant referral and waitlisting by an estimated period of 1.9 median years.^{48,53}

In a study of referral patterns to an urban nephrology academic practice, non-White individuals had 5.6 times higher odds of delayed referral than White individuals.⁵⁴ Numerous studies further demonstrate that Black, Hispanic, and Asian individuals receive less pre-end-stage kidney disease (ESKD) nephrology care than their White counterparts⁵⁵ for multiple reasons including time required to coordinate care, lack of integrated medical records, the lack of coordinated care between primary care and nephrology providers, inconsistent health care coverage mechanisms, and inconsistently applied standards for practice referral and CKD care such as those applied in the VA system.^{17,44,55} Later referrals to transplant and nephrology care for Black individuals compared with others have been demonstrated to result in substantial racial disparities in mortality.^{56–59}

Referral for Transplant

Inequalities in socioeconomic status (eg, income, health insurance status) and individuals' social contexts, which are shaped by structural racism and other forms of structured inequality, have been associated with racial inequities in transplant referrals.^{43,44} For instance, Black patients are more likely than others to be uninsured, and less likely than others to have a private insurer, which has been associated with lower rates of transplant evaluations among Black patients.^{43,44,60} Neighborhood factors (including neighborhood poverty) have also been associated with transplant referral^{47,61} and waitlist.^{62,63} For instance, African American patients had 37% lower odds of being pre-emptively referred for evaluation than White individuals after adjusting for patient, clinical, individual socioeconomic status and neighborhood factors, despite constituting the majority of patients with ESKD in the Southeast (66%) and the bulk of patients referred for evaluation overall.⁶⁴ Other studies have determined that although Black race is associated with significantly longer median wait times between dialysis initiation and waitlisting, positive associations between race, having Medicare due to disability, and living in neighborhood poverty are also substantial contributors to racial disparities.¹⁰ In one U.S. study, the odds of not being assessed for kidney transplant at the time of dialysis initiation were 1.05 (CI: 1.04–1.07) among Black individuals compared with others and 1.51 (CI: 1.30–1.75) among individuals without any insurance compared with individuals with insurance.⁶⁰ Unequal educational opportunity including in transplant education delivery, inequitable employment opportunities, and racial disparities in transportation have also been associated with racial disparities in transplant evaluations.^{61,62,65,66} Health care providers' inadequate understanding of racial inequities or misperceptions of “disinterest” among Black Americans⁶⁷ may also contribute to racial disparities in referral. For example, only 19% of dialysis facility providers in a national survey were aware of racial disparities in waitlisting. Providers practicing in dialysis facilities within the Southern United States (compared with the North East) (OR 3.05, CI: 10.4–8.94) and those with a low (compared with high) percent-age of Black patients (OR 1.86, CI: 1.02–3.39) were more likely to be unaware of racial disparities.⁶⁸

Transplant Evaluation and Waitlisting

After referral, Black individuals face additional barriers to receipt of kidney transplants. For instance, in a study of adult patients already referred for kidney transplant in the Southeastern United States, Black individuals had a lower relative hazard of transplant

than White individuals (hazard ratio [HR]: 0.41 CI: 0.28–0.58) even after adjusting for demographic, clinical, and other socioeconomic factors.⁴⁷ The interaction between poverty and racism may also be a potent one, requiring further study. For instance, although median distance from patient homes to transplant center did not predict waitlisting, race and neighborhood poverty were associated with waitlisting, and as the level of poverty increased, the likelihood of waitlisting decreased for Black vs White individuals.⁶¹ In another study, Black individuals had higher rates of referral than White non-Hispanic individuals (HR: 1.22 [CI 1.18–1.27]); however, they had lower rates of initiating the transplant evaluation process (HR: 0.93 [CI: 0.88–0.98]).⁴⁵ Some studies have indicated patients' experiences of racial and other discrimination may influence patient willingness to initiate transplant evaluations.^{69,70}

Specific aspects of the transplant evaluation process itself may also be subject to biases which contribute to racial inequities in transplant waitlisting. A systematic review of waitlisting guidelines revealed that recommendations are somewhat consistent across guidelines that embody medical criteria. However, differences in guidelines exist with regard to the importance of age, medical comorbidity, life expectancy, and especially with regard to psychosocial considerations in the evaluation process.⁷¹ For instance, the American Society of Transplantation has recommended that all patients have a psychosocial assessment conducted by a licensed professional using measurement tools completed by patients and clinicians. However, guidelines regarding the nature of these evaluations are not established, thus opening the door to potential biases and disparities among providers and centers.^{72,73} Notably, there is a lack of consensus regarding national standards by which psychosocial evaluations are conducted.⁷⁴ The lack of objective criteria for these assessments spurred the development of validated tools that assess psychosocial risk including the Psychosocial Assessment of Candidates for Transplantation,⁷³ Transplant Evaluation Rating Scale,⁷⁵ and the Stanford Integrated Psychosocial Assessment for Transplantation.⁷⁶ Each of these instruments assesses key domains essential for a psychosocial transplant evaluation including psychiatric (eg, coping, adjustment, substance use), social (collaboration, social support, housing, financial status), and functional status (eg, adherence, values, motivation, etc.).^{74,77} However, these instruments may be subject to bias in and of themselves. These instruments often consist of multicomponent evaluation through which there are several potential opportunities for bias to influence the assessment (Table 1). A survey of transplant program criteria for psychosocial evaluation suggest assessment on these factors (including dietary noncompliance) were considered relative contraindications to kidney transplantation, as was poor understanding of transplant, denial of illness severity, and use of addictive drugs in the last 6 months.⁷² Nonstandard assessments in these areas could allow for bias toward eliminating socially disadvantaged individuals (who are often Black) and may not account for structurally competent supportive actions which may have been taken to overcome these factors. For instance, in the case of 'dietary noncompliance', it would be important to consider numerous factors that may contribute, including the limited availability of health-promoting foods within a patient's neighborhood as well as financial/resource limitations.^{78–81}

Social support is also considered in the evaluation of transplant candidates because of its association with medical adherence (eg, immune suppression regimens) and overall

health.^{82–85} Poor social support has been noted to be associated with negative outcomes including graft survival, although data supporting this have been more mixed and inconsistent,^{82,86} with meta-analyses of this demonstrating a lack of clear association between social support and post-transplant outcomes including adherence.⁸⁷ It is important to consider how strict criteria for evaluating social support may disproportionately limit transplantation to marginalized individuals, who may be more likely to have caregivers/supportive partners who are less able to come to all critical appointments (eg, due to working multiple jobs or because of other caregiving concerns, transportation barriers).⁸⁸ Ethicists have noted historical examples of how prioritization of people with certain social support structures (eg, prioritizing people with families for dialysis receipt) has been contentious, discriminatory, and potentially unjust.⁸⁶ Some studies have demonstrated inconsistencies in the use of social support-based decisions, as well as the prevalence of perceived unfairness of this process, and its disproportionate impact on patients with low socioeconomic status.^{89,90} For instance, in a national study of national transplant providers, 10–22% of candidates were estimated to have been excluded because of inadequate support in the prior year, with only 52% of providers believing this was a modifiable factor.⁸⁹

Other behavioral assessments may also influence racial kidney transplant disparities. For instance, determination of substance use and its role as a relative or full contraindication to transplant waitlisting is marked by substantial variability in center-level practices and tolerance and may be subject to bias. For example, a White individual with an opiate dependence may be treated differently from other individuals (eg, using less highly stigmatizing language like opiate vs narcotic) in the medical record.⁹¹ Differential approaches to agents like marijuana in U.S. centers are also notable.^{92,93} Although some centers may have lenient standards, many centers reject all candidates registering marijuana use, in part because of concerns for association between dependence with other psychiatric comorbidities and substance use disorders that have negative implications for overall graft function.^{94,95} These discrepancies and lack of objective criteria to standardize practice patterns leave room for individual- and center-level bias.^{96,97}

ROLE OF MULTILEVEL SOCIO-CONTEXTUAL INFLUENCES ON THE PATHWAY TO TRANSPLANT

Little work has been carried out to explore how socio-contextual factors at the individual, interpersonal, systemic, or societal barriers may work jointly to impact transplant racial inequities.⁹⁸ For example, one of the leading reasons for inactive status among new transplant listings includes incomplete candidate workups (66.8%).⁹⁹ These incomplete workups may not simply reflect individuals' personal fears, knowledge or beliefs, or intrinsic capabilities. Rather, they may reflect a complex set of socio-contextual personal experiences (eg, prior discrimination increasing a sense of low trust in the system)⁶⁹ as well as system-level barriers including financial strain due to lack of universal health care coverage for preventive services or lack of equity in employment opportunity.¹⁰⁰

Neighborhood contexts are also associated with racial disparities in kidney transplant receipt. For instance, in an early study of transplant waitlisting among individuals with

ESKD living in the Southeastern United States, increased neighborhood poverty was associated with decreased likelihood of waitlisting among Black individuals compared with White individuals in all poverty categories.⁶¹ This work has been corroborated in other examinations of the association between neighborhood poverty, racial composition, and waitlisting.^{47,61} In one study, Black individuals in poor predominantly Black neighborhoods (adjusted HR 0.57, CI: 0.53–0.62) were less likely to be waitlisted than those in wealthy Black neighborhoods (HR 0.80, CI: 0.67–0.96) and in poor primarily White neighborhoods (HR 0.79, CI: 0.70–0.89).⁶³

Financial barriers to kidney transplantation are also a key driver of racial inequity in kidney transplantation in the United States. Individuals with limited finances are less likely to receive living donor kidney transplants¹⁰¹ and/or pre-emptive transplants.¹⁰² Transplant recipients have higher income and fewer concerns regarding transplant costs than nonrecipients.¹⁰³ Health care insurance type (eg, private insurance which may cover more high-income workers) has also been associated with higher transplant survival, as well as rates and duration of waitlisting.^{20,104–106} In addition, in qualitative investigations, African American and non-African American pretransplant patients expressed many concerns regarding costs of transplant and donor evaluation, as well as post-transplantation financial fears (cost of immune suppression, loss of insurance) and living donor experiences.¹⁰⁴ In several studies, financial concerns outweighed fears about transplantation, specifically concerns about transportation, scheduling, the operation, and medications and their coverage after transplant.^{27,101,102}

FORGING A PATH TOWARD EQUITY: ENHANCING STRUCTURAL COMPETENCY AND APPLYING AN EQUITY LENS TO EVALUATION

Despite our best efforts to individualize patients' care and increase transplant access and receipt, our efforts may fail when we cannot recognize biases and other structural barriers to kidney transplantation. To begin to forge a path toward equity, nephrology professionals may benefit from enhancing our structural competency—our understanding of how complex social institutions including health insurance,^{107,108} immigration policy,¹⁰⁹ and housing agencies^{110,111} influence kidney health, transplant access, and behaviors.¹¹² This also requires that professionals address the compounded and intersectional experiences of individuals for whom forms of marginalization occur across multiple identity domains (eg, race, gender, sexual orientation).¹¹³ In Table 2, we suggest key approaches for achieving equity in transplant evaluation using a structurally competent lens.

First, pretransplant kidney care should strive to be structurally competent, thus recognizing and addressing that structural/social-contextual factors are vital in shaping our patients' lives, opportunities, health, and behaviors.¹¹⁴ More specifically, individual behaviors (antihypertension medication adherence, diabetes control) should be considered as a product of an individual's sociopolitical context (eg, adherence issues would be considered in the context of medication physical and financial availability) instead of through a lens which places blame or full responsibility on the individual. Structural solutions would allow centers and providers to account for neighborhood and other structural barriers to equity

(eg, addressing lack of insurance, inequitable education, and barriers to kidney-promoting medications including sodium-glucose co-transporter-2 inhibitors) in the financial, social support, and psychosocial domains.

Second, transplant referral processes should be reviewed and executed through an equity and structural competency lens. Dialysis and general nephrology providers should be equipped with antibias training and transparent metrics for determining who is referred for transplantation so that potentially biased factors (eg, adherence to insulin if affordability is a key barrier) do not unduly impede transplant. A structurally competent referral process would require transparency about criteria and iterative review of factors impeding referral among individuals, during which a careful evaluation of financial, social support, and other barriers could be addressed (eg, social support/availability of donors, financial needs and concerns, income). Each of these interventions would require multidisciplinary collaboration and advocacy that places the needs of marginalized individuals at the center of “intervention” development.¹¹⁵ This may also require collaboration and long-term investments in mental health and other infrastructures that promote health (eg, safety, access to high-quality education, food, housing, expanded insurance access).

In addition to enhancing structural competency among transplant center providers, greater clarity and transparency are needed regarding center-level/national criteria for the psychosocial assessment of patients. Clear measures to reduce interpersonal explicit or implicit biases³⁴ that may interfere with evaluation, including around trauma, are needed. More comprehensive holistic and nuanced evaluation of candidates in which implicit and explicit biases are mitigated could aid efforts to avoid producing inequities in transplant candidacy.

CONCLUSION

Equity—or ensuring equal chances of tailored treatment and resource delivery to patients with varying social contexts and circumstances—is essential in transplantation. Decades-long stark racial and ethnic disparities continue to persist in the United States. A cascade of structural barriers across the kidney transplant journey provides important targets for intervention. Structural competency—or a comprehensive recognition of how institutions, neighborhood infrastructure and contexts, economic forces, public policies, and health care systems impact individual health and behaviors—is essential to addressing these structural barriers and enhancing racial transplant equity.

Support:

D.M. and L.M.M. were supported by the Duke Center for Research to Advance Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities under award number U54MD012530.

REFERENCES

1. Reese PP, Mohan S, King KL, et al. Racial disparities in preemptive waitlisting and deceased donor kidney transplantation: Ethics and solutions. *Am J Transplant*. 2021;21(3):958–967. [PubMed: 33151614]

2. Ng Y-H, Pankratz VS, Leyva Y, et al. Does racial disparity in kidney transplant waitlisting persist after accounting for social Determinants of health? *Transplantation*. 2020;104(7):1445–1455. [PubMed: 31651719]
3. Epstein AM, Ayanian JZ, Keogh JH, et al. Racial disparities in access to renal transplantation—clinically appropriate or due to under-use or overuse? *New Engl J Med*. 2000;343(21):1537–1544. 1532 p preceding 1537. [PubMed: 11087884]
4. System URD. 2019 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2019. Chapter 6.
5. Melanson TA, Hockenberry JM, Plantinga L, et al. New kidney allocation system Associated with increased rates of transplants among black and Hispanic patients. *Health Aff*. 2017;36(6):1078–1085.
6. Massie AB, Luo X, Lonze BE, et al. Early Changes in kidney Distribution under the new allocation system. *J Am Soc Nephrol*. 2016;27(8):2495–2501. [PubMed: 26677865]
7. King KL, Husain SA, Jin Z, Brennan C, Mohan S. Trends in disparities in preemptive kidney transplantation in the United States. *Clin J Am Soc Nephrol*. 2019;14(10):1500–1511. [PubMed: 31413065]
8. Zhang X, Melanson TA, Plantinga LC, et al. Racial/ethnic disparities in waitlisting for deceased donor kidney transplantation 1 year after implementation of the new national kidney allocation system. *Am J Transpl*. 2018;18(8):1936–1946.
9. Arriola KJ. Race, racism, and access to renal transplantation among African Americans. *J Health Care Poor Underserved*. 2017;28(1):30–45. [PubMed: 28238984]
10. Joshi S, Gaynor JJ, Bayers S, et al. Disparities among Blacks, Hispanics, and Whites in time from starting dialysis to kidney transplant waitlisting. *Transplantation*. 2013;95(2):309–318. [PubMed: 23325005]
11. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. *Transplantation*. 2002;74(10):1377–1381. [PubMed: 12451234]
12. Haller MC, Kainz A, Baer H, Oberbauer R. Dialysis vintage and outcomes after kidney transplantation: a Retrospective Cohort study. *Clin J Am Soc Nephrol*. 2017;12(1):122–130. [PubMed: 27895135]
13. Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. *Kidney Int*. 1998;53(3):767–772. [PubMed: 9507225]
14. Purnell TS, Luo X, Cooper LA, et al. Association of race and ethnicity with live donor kidney transplantation in the United States from 1995 to 2014. *Jama*. 2018;319(1):49–61. [PubMed: 29297077]
15. Rodrigue JR, Kazley AS, Mandelbrot DA, Hays R, LaPointe Rudow D, Baliga P. Living donor kidney transplantation: Overcoming disparities in live kidney Donation in the US—Recommendations from a consensus conference. *Clin J Am Soc Nephrol*. 2015;10(9):1687–1695. [PubMed: 25883072]
16. Purnell TS, Simpson DC, Callender CO, Boulware LE. Dismantling structural racism as a root cause of racial disparities in COVID-19 and transplantation. *Am J Transplant*. 2021;21(7):2327–2332. [PubMed: 33599027]
17. Purnell TS, Bae S, Luo X, et al. National Trends in the association of race and ethnicity with predialysis nephrology care in the United States from 2005 to 2015. *JAMA Netw Open*. 2020;3(8):e2015003. [PubMed: 32852554]
18. Purnell TS, Crews DC. Persistent disparities in preemptive kidney transplantation. *Clin J Am Soc Nephrol*. 2019;14(10):1430–1431. [PubMed: 31558484]
19. Rudow DL, Hays R, Baliga P, et al. Consensus conference on best practices in live kidney Donation: recommendations to Optimize education, access, and care. *Am J Transpl*. 2015;15(4):914–922.
20. Schold JD, Gregg JA, Harman JS, Hall AG, Patton PR, Meier-Kriesche HU. Barriers to evaluation and wait listing for kidney transplantation. *Clin J Am Soc Nephrol*. 2011;6(7):1760–1767. [PubMed: 21597030]

21. Weng FL, Joffe MM, Feldman HI, Mange KC. Rates of completion of the medical evaluation for renal transplantation. *Am J Kidney Dis.* 2005;46(4):734–745. [PubMed: 16183429]
22. Wolfe RA, Ashby VB, Milford EL, et al. Differences in access to cadaveric renal transplantation in the United States. *Am J kidney Dis.* 2000;36(5):1025–1033. [PubMed: 11054361]
23. Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. *Am J Kidney Dis.* 2004;44(3):529–542. [PubMed: 15332226]
24. Rodríguez JE, Campbell KM. Racial and ethnic disparities in prevalence and care of patients with type 2 diabetes. *Clin Diabetes.* 2017;35(1):66–70. [PubMed: 28144049]
25. Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. *Adv Chronic Kidney Dis.* 2010;17(3):225–236. [PubMed: 20439091]
26. Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. *J Am Soc Nephrol.* 2002;13(5):1358–1364. [PubMed: 11961024]
27. Kazley AS, Simpson KN, Chavin KD, Baliga P. Barriers facing patients referred for kidney transplant cause loss to follow-up. *Kidney Int.* 2012;82(9):1018–1023. [PubMed: 22832516]
28. Nickolas TL, Frisch GD, Opatowsky AR, Arons R, Radhakrishnan J. Awareness of kidney disease in the US population: findings from the national health and Nutrition examination survey (NHANES) 1999 to 2000. *Am J Kidney Dis.* 2004;44(2):185–197. [PubMed: 15264176]
29. Waterman AD, Browne T, Waterman BM, Gladstone EH, Hostetter T. Attitudes and behaviors of African Americans regarding early detection of kidney disease. *Am J Kidney Dis.* 2008;51(4):554–562. [PubMed: 18371531]
30. Boulware LE, Carson KA, Troll MU, Powe NR, Cooper LA. Perceived susceptibility to chronic kidney disease among high-risk patients seen in primary care practices. *J Gen Intern Med.* 2009;24(10):1123–1129. [PubMed: 19711135]
31. Finkelstein FO, Story K, Firanek C, et al. Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies. *Kidney Int.* 2008;74(9):1178–1184. [PubMed: 18668024]
32. Powe NR, Melamed ML. Racial disparities in the Optimal delivery of chronic kidney disease care. *Med Clin North America.* 2005;89(3):475–488.
33. Charles RF, Powe NR, Jaar BG, Troll MU, Parekh RS, Boulware LE. Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians. *Am J Kidney Dis.* 2009;54(2):227–237. [PubMed: 19371991]
34. Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. *Am J Public Health.* 2015;105(12):e60–e76.
35. Peek ME, Gorawara-Bhat R, Quinn MT, Odoms-Young A, Wilson SC, Chin MH. Patient trust in physicians and shared decision-making among African-Americans with diabetes. *Health Commun.* 2013;28(6):616–623. [PubMed: 23050731]
36. Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. *Arch Intern Med.* 2005;165(18):2098–2104. [PubMed: 16216999]
37. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. *Diabetes Care.* 1999;22(3):403–408. [PubMed: 10097918]
38. Golden SH, Joseph JJ, Hill-Briggs F. Casting a health equity lens on Endocrinology and diabetes. *The J Clin Endocrinol Metab.* 2021;106(4):e1909–e1916. [PubMed: 33496788]
39. Murphy KA, Greer RC, Roter DL, et al. Awareness and discussions about chronic kidney disease among African-Americans with chronic kidney disease and hypertension: a mixed methods study. *J Gen Intern Med.* 2020;35(1):298–306. [PubMed: 31720962]
40. Greer RC, Cooper LA, Crews DC, Powe NR, Boulware LE. Quality of patient-physician discussions about CKD in primary care: a cross-sectional study. *Am J Kidney Dis.* 2011;57(4):583–591. [PubMed: 21131116]

41. Eberly LA, Yang L, Eneanya ND, et al. Association of race/ethnicity, gender, and socioeconomic status with Sodium-Glucose Cotransporter 2 inhibitor Use among patients with diabetes in the US. *JAMA Netw Open*. 2021;4(4):e216139. [PubMed: 33856475]
42. Vassalotti JA, Centor R, Turner BJ, et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. *The Am J Med*. 2016;129(2):153–162.e157. [PubMed: 26391748]
43. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. *BMC Nephrol*. 2008;9(Feb 25):3. [PubMed: 18298850]
44. Navaneethan SD, Kandula P, Jeevanantham V, Nally JV Jr, Liebman SE. Referral patterns of primary care physicians for chronic kidney disease in general population and geriatric patients. *Clin Nephrol*. 2010;73(4):260–267. [PubMed: 20353733]
45. Patzer RE, McPherson L, Wang Z, et al. Dialysis facility referral and start of evaluation for kidney transplantation among patients treated with dialysis in the Southeastern United States. *Am J Transplant*. 2020;20(8):2113–2125. [PubMed: 31981441]
46. Patzer RE, Paul S, Plantinga L, et al. A Randomized Trial to reduce disparities in referral for transplant evaluation. *J Am Soc Nephrol*. 2017;28(3):935–942. [PubMed: 27738125]
47. Patzer RE, Perryman JP, Schrage JD, et al. The role of race and poverty on steps to kidney transplantation in the Southeastern United States. *Am J Transpl*. 2012;12(2):358–368.
48. Boulware LE, Purnell TS, Mohottige D. Systemic kidney transplant inequities for black individuals: Examining the contribution of racialized kidney function estimating equations. *JAMA Netw Open*. 2021;4(1):e2034630. [PubMed: 33443577]
49. Eneanya ND, Yang W, Reese PP. Reconsidering the Consequences of using race to estimate kidney function. *JAMA*. 2019;322(2):113–114. [PubMed: 31169890]
50. Norris KC, Eneanya ND, Boulware LE. Removal of race from estimates of kidney function: first, do no harm. *JAMA*. 2021;325(2):135–137. [PubMed: 33263722]
51. Grubbs V Precision in GFR reporting. Let's stop playing the race card. *Clin J Am Soc Nephrol*. 2020;15(8):1201–1202. [PubMed: 32401730]
52. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604–612. [PubMed: 19414839]
53. Zelnick LR, Leca N, Young B, Bansal N. Estimation of glomerular filtration rate with vs. without the race coefficient and time to eligibility for kidney transplant. *JAMA Netw Open*. 2021;4(1):e2034004. 10.1001/jamanetworkopen.2020.34004. [PubMed: 33443583]
54. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, Hispanic, and older patients with chronic renal failure. *Am J Kidney Dis*. 1999;33(4):728–733. [PubMed: 10196016]
55. Nee R, Yuan CM, Hurst FP, Jindal RM, Agodoa LY, Abbott KC. Impact of poverty and race on pre-end-stage renal disease care among dialysis patients in the United States. *Clin Kidney J*. 2017;10(1):55–61. [PubMed: 28638604]
56. Yan G, Cheung AK, Ma JZ, et al. The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. *Clin J Am Soc Nephrol*. 2013;8(4):610–618. [PubMed: 23493380]
57. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. *Ann Intern Med*. 2002;137(6):479–486. [PubMed: 12230348]
58. Jungers P, Massy ZA, Nguyen-Khoa T, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. *Nephrol Dial Transplant*. 2001;16(12):2357–2364. [PubMed: 11733627]
59. McClellan WM, Wasse H, McClellan AC, Kipp A, Waller LA, Rocco MV. Treatment center and geographic variability in pre-ESRD care associate with increased mortality. *J Am Soc Nephrol*. 2009;20(5):1078–1085. [PubMed: 19321704]
60. Johansen KL, Zhang R, Huang Y, Patzer RE, Kutner NG. Association of race and insurance type with delayed assessment for kidney transplantation among patients initiating dialysis in the United States. *Clin J Am Soc Nephrol*. 2012;7(9):1490–1497. [PubMed: 22837273]

61. Patzer RE, Amaral S, Wasse H, Volkova N, Kleinbaum D, McClellan WM. Neighborhood poverty and racial disparities in kidney transplant waitlisting. *J Am Soc Nephrol*. 2009;20(6):1333–1340. [PubMed: 19339381]
62. Schold JD, Heaphy ELG, Buccini LD, et al. Prominent impact of Community risk factors on kidney transplant candidate processes and outcomes. *Am J Transplant*. 2013;13(9):2374–2383. [PubMed: 24034708]
63. Saunders M, Cagney K, Ross L, Alexander GC. Neighborhood poverty, racial composition and renal transplant waitlist. *Am J Transplant*. 2010;10(8):1912–1917. [PubMed: 20659097]
64. Gander JC, Zhang X, Plantinga L, et al. Racial disparities in preemptive referral for kidney transplantation in Georgia. *Clin Transplant*. 2018;32(9):e13380. [PubMed: 30099781]
65. Plantinga L, Pastan S, Kramer M, McClellan A, Krisher J, Patzer RE. Association of U.S. Dialysis facility neighborhood characteristics with facility-level kidney transplantation. *Am J Nephrol*. 2014;40(2):164–173. [PubMed: 25196018]
66. Peng RB, Lee H, Ke ZT, Saunders MR. Racial disparities in kidney transplant waitlist appearance in Chicago: is it race or place? *Clin Transplant*. 2018;32(5):e13195. [PubMed: 29430739]
67. Ayanian JZ, Cleary PD, Keogh JH, Noonan SJ, David-Kasdan JA, Epstein AM. Physicians' beliefs about racial differences in referral for renal transplantation. *Am J Kidney Dis*. 2004;43(2): 350–357. [PubMed: 14750101]
68. Kim JJ, Basu M, Plantinga L, et al. Awareness of racial disparities in kidney transplantation among health care providers in dialysis facilities. *Clin J Am Soc Nephrol*. 2018;13(5):772–781. [PubMed: 29650714]
69. Hamoda RE, McPherson LJ, Lipford K, et al. Association of sociocultural factors with initiation of the kidney transplant evaluation process. *Am J Transpl*. 2020;20(1):190–203.
70. Myaskovsky L, Almario Doebler D, Posluszny DM, et al. Perceived discrimination predicts longer time to be accepted for kidney transplant. *Transplantation*. 2012;93(4):423–429. [PubMed: 22228417]
71. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? *Transplantation*. 2012;94(7):703–713. [PubMed: 22948443]
72. Levenson JL, Olbrisch ME. Psychosocial evaluation of organ transplant candidates: a comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. *Psychosomatics*. 1993;34(4):314–323. [PubMed: 8351306]
73. Olbrisch ME, Levenson JL, Hamer R. The PACT: a rating scale for the study of clinical decision-making in psychosocial screening of organ transplant candidates. *Clin Transplant*. 1989;3(3):164–169.
74. Lewandowski AN, Skillings JL. Who gets a lung transplant? Assessing the psychosocial decision-making process for transplant listing. *Glob Cardiol Sci Pract*. 2016;2016(3):e201626. [PubMed: 29043272]
75. Twillman RK, Manetto C, Wellisch DK, Wolcott DL. The Transplant Evaluation Rating Scale. A revision of the psychosocial levels system for evaluating organ transplant candidates. *Psychosomatics*. 1993;34(2):144–153. [PubMed: 8456157]
76. Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. *Psychosomatics*. 2012;53(2):123–132. [PubMed: 22424160]
77. Skillings JL, Lewandowski AN. Team-based Biopsychosocial care in Solid organ transplantation. *J Clin Psychol Med Settings*. 2015;22(2–3):113–121. [PubMed: 26260917]
78. Grier SA, Kumanyika SK. The context for choice: health implications of targeted food and beverage marketing to African Americans. *Am J Public Health*. 2008;98(9):1616–1629. [PubMed: 18633097]
79. Gustafson AA, Sharkey J, Samuel-Hodge CD, et al. Perceived and objective measures of the food store environment and the association with weight and diet among low-income women in North Carolina. *Public Health Nutr*. 2011;14(6):1032–1038. [PubMed: 21324229]

80. Gutierrez OM, Anderson C, Isakova T, et al. Low socioeconomic status associates with higher serum phosphate irrespective of race. *J Am Soc Nephrol.* 2010;21(11):1953–1960. [PubMed: 20847142]
81. Suarez JJ, Isakova T, Anderson CAM, Boulware LE, Wolf M, Scialla JJ. Food access, chronic kidney disease, and hypertension in the U.S. *Am J Prev Med.* 2015;49(6):912–920. [PubMed: 26590940]
82. Maldonado JR. Why it is important to consider social support when assessing organ transplant candidates? *Am J Bioeth.* 2019;19(11):1–8.
83. Dobbels F, Vanhaecke J, Desmytere A, Dupont L, Nevens F, De Geest S. Prevalence and correlates of self-reported pretransplant nonadherence with medication in heart, liver, and lung transplant candidates. *Transplantation.* 2005;79(11):1588–1595. [PubMed: 15940050]
84. Dew MA, DiMartini AF, Dobbels F, et al. The approach to the psychosocial evaluation of Cardiac transplant and Mechanical Circulatory support candidates. *Curr Heart Fail Rep.* 2019;16(6):201–211. [PubMed: 31782078]
85. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. *Health Psychol.* 2004;23(2):207. [PubMed: 15008666]
86. Berry KN, Daniels N, Ladin K. Should lack of social support prevent access to organ transplantation? *Am J Bioeth.* 2019;19(11):13–24.
87. Ladin K, Daniels A, Osani M, Bannuru RR. Is social support associated with post-transplant medication adherence and outcomes? A systematic review and meta-analysis. *Transplant Rev.* 2018;32(1):16–28.
88. Harknett KS, Hartnett CS. Who lacks support and Why? An examination of Mothers' personal safety Nets. *J Marriage Fam.* 2011;73(4):861–875. [PubMed: 22199402]
89. Ladin K, Emerson J, Berry K, et al. Excluding patients from transplant due to social support: Results from a national survey of transplant providers. *Am J Transpl.* 2019;19(1):193–203.
90. Ladin K, Emerson J, Butt Z, et al. How important is social support in determining patients' suitability for transplantation? Results from a National Survey of Transplant Clinicians. *J Med Ethics.* 2018;44(10):666–674. [PubMed: 29954874]
91. P Goddu A, O'Connor KJ, Lanzkron S, et al. Do Words Matter? stigmatizing language and the Transmission of bias in the medical record. *J Gen Intern Med.* 2018;33(5):685–691. [PubMed: 29374357]
92. Heinrich TW, Marcangelo M. Psychiatric issues in Solid organ transplantation. *Harv Rev Psychiatry.* 2009;17(6):398–406. [PubMed: 19968454]
93. Lentine KL, Salvalaggio PR, Caliskan Y, et al. Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: analysis of linked transplant registry and pharmacy fill records. *J Heart Lung Transplant.* 2021;40(6):513–524. [PubMed: 33846078]
94. Rai HS, Winder GS. Marijuana Use and organ transplantation: a review and implications for clinical practice. *Curr Psychiatry Rep.* 2017;19(11):91. [PubMed: 29075929]
95. Rein JL. The nephrologist's guide to cannabis and cannabinoids. *Curr Opin Nephrol Hypertens.* 2020;29(2):248–257. [PubMed: 31972598]
96. Gerrard M, Stock ML, Roberts ME, et al. Coping with racial discrimination: the role of substance use. *Psychol Addict Behaviors.* 2012;26(3):550.
97. Assari S, Mistry R, Lee DB, Caldwell CH, Zimmerman MA. Perceived racial discrimination and marijuana use a decade later; gender differences among Black youth. *Front Pediatr.* 2019;7(78). 10.3389/fped.2019.00078, <https://www.frontiersin.org/article/10.3389/fped.2019.00078>.
98. Wesselman H, Ford CG, Leyva Y, et al. Social Determinants of health and race disparities in kidney transplant. *Clin J Am Soc Nephrol.* 2021;16(2):262–274. [PubMed: 33509963]
99. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2018 Annual data report: kidney. *Am J Transplant.* 2020;20(s1):20–130. [PubMed: 31898417]
100. Monson RS, Kemerley P, Walczak D, Benedetti E, Oberholzer J, Danielson KK. Disparities in completion rates of the medical prerenal transplant evaluation by race or ethnicity and gender. *Transplantation.* 2015;99(1):236–242. [PubMed: 25531896]

101. Rodrigue JR, Reed AI, Nelson DR, Jamieson I, Kaplan B, Howard RJ. The financial burden of transplantation: a single-center survey of liver and kidney transplant recipients. *Transplantation*. 2007;84(3):295–300. [PubMed: 17700152]
102. Dageforde LA, Box A, Feurer ID, Cavanaugh KL. Understanding patient barriers to kidney transplant evaluation. *Transplantation*. 2015;99(7):1463–1469. [PubMed: 25606794]
103. Coorey GM, Paykin C, Singleton-Driscoll LC, Gaston RS. Barriers to preemptive kidney transplantation. *AJN The Am J Nurs*. 2009;109(11):28–37.
104. Ganji S, Ephraim PL, Ameling JM, Purnell TS, Lewis-Boyer LL, Boulware LE. Concerns regarding the financial aspects of kidney transplantation: perspectives of pre-transplant patients and their family members. *Clin Transplant*. 2014;28(10):1121–1130. [PubMed: 25066730]
105. Schold JD, Sehgal AR, Srinivas TR, Poggio ED, Navaneethan SD, Kaplan B. Marked variation of the association of ESRD duration before and after wait listing on kidney transplant outcomes. *Am J Transpl*. 2010;10(9):2008–2016.
106. Keith D, Ashby VB, Port FK, Leichtman AB. Insurance type and minority status associated with large disparities in prelisting dialysis among candidates for kidney transplantation. *Clin J Am Soc Nephrol*. 2008;3(2):463–470. [PubMed: 18199847]
107. Harhay MN, McKenna RM, Boyle SM, et al. Association between Medicaid Expansion under the affordable care Act and preemptive listings for kidney transplantation. *Clin J Am Soc Nephrol*. 2018;13(7):1069–1078. [PubMed: 29929999]
108. Mohottige D, Diamantidis CJ, Norris KC, Boulware LE. Racism and kidney health: turning equity into a reality. *Am J Kidney Dis*. 2021;77(6):951–962. [PubMed: 33639186]
109. Cervantes L, Tuot D, Raghavan R, et al. Association of emergency-only vs standard hemodialysis with mortality and health care use among undocumented immigrants with end-stage renal disease. *JAMA Intern Med*. 2018;178(2):188–195. [PubMed: 29255898]
110. Crews DC, Novick TK. Social Determinants of CKD Hotspots. *Semin Nephrol*. 2019;39(3):256–262. [PubMed: 31054624]
111. Novick TK, Gadegbeku CA, Crews DC. Dialysis for patients with end-stage renal disease who are Homeless. *JAMA Intern Med*. 2018;178(12):1581–1582. [PubMed: 30398536]
112. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. *The Lancet*. 2017;389(10077):1453–1463.
113. Crenshaw K. Mapping the Margins: Intersectionality, identity Politics, and Violence against women of color. *Stanford L Rev*. 1991;43(6):1241–1299.
114. Metzl JM, Hansen H. Structural competency: theorizing a new medical engagement with stigma and inequality. *Soc Sci Med*. 2014;103:126–133. [PubMed: 24507917]
115. Ford CL, Airhihenbuwa CO. Critical Race Theory, race equity, and public health: toward antiracism praxis. *Am J Public Health*. 2010;100(Suppl 1):S30–S35. [PubMed: 20147679]
116. Waterman AD, Peipert JD, Hyland SS, McCabe MS, Schenk EA, Liu J. Modifiable patient characteristics and racial disparities in evaluation completion and living donor transplant. *Clin J Am Soc Nephrol*. 2013;8(6):995–1002. [PubMed: 23520044]
117. Waterman AD, Peipert JD, McSorley A-M, Goalby CJ, Beaumont JL, Peace L. Direct delivery of kidney transplant education to Black and low-income patients receiving dialysis: a randomized controlled trial. *Am J Kidney Dis*. 2019;74(5):640–649. [PubMed: 31227225]
118. Beyer KMM, Laud PW, Zhou Y, Nattinger AB. Housing discrimination and racial cancer disparities among the 100 largest US metropolitan areas. *Cancer*. 2019;125(21):3818–3827. [PubMed: 31287559]
119. Baker FM, Bell CC. Issues in the psychiatric treatment of African Americans. *Psychiatr Serv*. 1999;50(3):362–368. [PubMed: 10096640]
120. Stockdale SE, Wells KB, Tang L, Belin TR, Zhang L, Sherbourne CD. The importance of social context: neighborhood stressors, stress-buffering mechanisms, and alcohol, drug, and mental health disorders. *Soc Sci Med*. 2007;65(9):1867–1881. [PubMed: 17614176]
121. Boulware LE, Mohottige D. The seen and the unseen: race and social inequities affecting kidney care. *Clin J Am Soc Nephrol*. 2021;16(5):815–817. [PubMed: 33441464]
122. Boulware LE, Sudan DL, Strigo TS, et al. Transplant social worker and donor financial assistance to increase living donor kidney transplants among African Americans: The TALKS Study, a

randomized comparative effectiveness trial. *Am J Transplant.* 2020;21(6):2175–2187. 10.1111/ajt.16403.

123. Mathur AK, Stewart Lewis ZA, Warren PH, et al. Best practices to optimize utilization of the National Living Donor Assistance Center for the financial assistance of living organ donors. *Am J Transplant.* 2020;20(1):25–33. [PubMed: 31680449]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

CLINICAL SUMMARY

- Structural barriers contribute to racial and ethnic disparities in kidney transplantation and occur during pretransplant kidney care, referral, and in the evaluation process.
- Structural competency, antiracist, and antibiased principles should be adopted by kidney and transplant care professionals to enhance equity.
- An equity lens should be applied when conducting psychosocial, financial, social support, and adherence evaluation during pretransplant kidney care, referral, and throughout the evaluation process.

Table 1. Recommended Domains for Transplant Psychosocial Evaluation, Example Items Assessed, and Potential Limitations of Assessment When Applying an Equity Lens

Domain for Assessment	Example Items Assessed	Potential Bias in Assessment Which Could Lead to Transplant Inequity
Functional	<p>Knowledge and understanding of medical illness process (that caused specific organ failure) and knowledge and understanding of the process of transplantation</p> <p>Willingness/desire for treatment (transplant)</p> <p>History of treatment adherence/compliance (pertinent to medical issues)</p> <p>Lifestyle factors (including diet, exercise, fluid restrictions, and other habits)</p>	<p>Racial disparities exist in transplant knowledge, education, and information delivery^{11,16,117}</p> <p>May be influenced by lack of trust mediated by personal, vicarious, or historical discrimination or abuse^{71,72}</p> <p>May be influenced by discrimination and social/structural barriers to ‘adhering’ (eg, lack of transport to the dialysis unit, lack of available fresh vegetables, safe spaces to engage in physical activity)</p> <p>Influenced by structural inequity (eg, food availability, physical access to safely exercise, income)</p>
Social	<p>Availability and function of social support system</p> <p>Appropriateness of physical living space and environment</p>	<p>The support network influenced by their circumstances and socio-contextual contexts (eg, financial strain, employment demands) and variations in workplace and other caregiving schedules⁸⁶</p> <p>Housing¹¹⁸ and infrastructure inequities are substantial across racial and ethnic lines and by other domains (eg, income, immigration status)</p>
Psychological	<p>Presence of psychopathology (other than personality disorders and organic psychopathology)</p> <p>Alcohol use, abuse, and dependence; risk for recidivism; illicit substance abuse and dependence and risk for recidivism, nicotine use, abuse, and dependence</p>	<p>Evidence suggests some racial minority groups may be more likely to be diagnosed with psychiatric disorders than White individuals¹¹⁹</p> <p>Ethnic/racial minoritized individuals may disproportionately experience psychosocial stressors (eg, trauma, discrimination)¹²⁰</p> <p>Extensive persistent disparities in access to mental health care disproportionately impact ethnic/racial minority individuals (vs. White individuals)</p>

Table 2.

Key Approaches for Achieving Equity in Transplant Evaluation

Consideration	Goal	Example	Potential Equity-promoting Actions
Pretransplant kidney care			
Psychosocial	Apply a structural competency lens to understand patients' kidney care behaviors (eg, CKD or dialysis self-management) Promote trauma-informed approaches	A patient with untreated mental health concerns may have difficulty with medication or dialysis adherence	Train kidney care providers in structurally competent care (eg, factors including social support, neighborhood resources influence coping and adherence) Advocate for mental health and comprehensive care Ensure accountability and transparency in psychosocial evaluation Provide interventions that reduce interpersonal explicit or implicit biases ³⁵ Address depression and low self-reported QoL, which may impair kidney transplant pursuit
Financial support	Promote equity-focused policy reform	A patient who is uninsured or underinsured may lack access to key interventions (eg, SGLT2 inhibitors) and resources (eg, healthy food access)	Promote reforms that expand access to insurance and coverage of key kidney health-promoting medications and resources (eg, LDKT education, SGLT2 inhibitors) Support policies that improve inequitable social contexts (eg, housing, education, food access, environmental safety)
Social support	Promote structural competency when determining social support (eg, family circumstances influence availability of caregivers) Engage community organizations and others in enhancing social support structures and kidney health education	A patient who is living alone without a vehicle/public transit but relying on multiple family members for transportation may have difficulty physically accessing care	Leverage community health workers via partnerships to enhance social support for kidney patients Promote policy reforms that account for complex family and social structures/resources to enhance care (eg, time off for loved one who is primary form of transportation, reimbursement for parking, respite care for caregivers)
Referral for transplantation			
Psychosocial considerations	Promote structural competency when assessing psychosocial domains Promote trauma-informed and structurally competent approaches Ensure clarity and transparency in referral criteria	A patient who has experienced prior personal trauma resulting in temporary unemployment may experience lapses in health care coverage and thus have difficulty completing key steps in the transplant evaluation process (eg, echocardiography, etc.) A patient who has experienced prior racial discrimination may have uncertainty re: initiation of transplant evaluation and may require additional tailored resources and support ¹²⁷	Ensure that all members of the dialysis team are trained in structurally competent care, antiracism, and antibias Partner with community organizations to disseminate information about transplant Advocate for policy reforms that support access to comprehensive health care Promote reforms that support mental health and psychosocial counseling for candidacy Ensure accountability and reduce interpersonal explicit or implicit biases ³⁵ that may interfere with transplant referral (eg, automated electronic medical systems that query why referrals have been made vs not) ¹²¹
Financial evaluation	Promote equity in financial evaluation Ensure accountability among dialysis and nephrology providers to promote referral when appropriate	A patient with unstable employment benefits may lack financial resources to ensure completion of the transplant workup	Support dialysis financial assistance programs that may mitigate barriers to patients considering transplant (eg, financial planning and saving discussions) Advocate for employment and insurance protection for donors and other equity-promoting reforms Support policies that improve inequitable social contexts that may be barriers to referral (eg, housing, education, food access, environmental) Support financial assistance programs including the National Living Donor Assistance Program ^{122,123}
Social support	Promote structural competency when assessing social support	Patients with multiple supportive family members who have significant employment demands may not	Demonstrate flexibility in the determination of social support based on the needs and availability of individuals within a patient's social network

Consideration	Goal	Example	Potential Equity-promoting Actions
Adherence	Ensure key equity criteria are consistently applied across all potential transplant candidates Promote structural competence when interpreting patient adherence	meet narrowly defined criteria for social support defined by centers (eg, a single person must be present at all meetings) A patient with financial barriers may have difficulty physically accessing nephrology care consistently	Ensure antiracist, unbiased education for all kidney care personnel Support educational efforts partnering with community organizations and other key social networks engaged with transplant referral Support expanded coverage for transportation and other barriers (cost of phosphorous binders) Apply equitable criteria for candidacy across all potential candidates
Transplant evaluation			
Psychosocial evaluation	Promote structural competence in evaluation Promote trauma-informed approaches	A patient who has experienced prior personal trauma resulting in temporary unemployment may experience lapses in health care coverage and thus have difficulty maintaining mental health care access	Ensure that all members of the transplant team are trained in structurally competent care, antiracist/antibias principles, and trauma-informed practices Advocate for policy reforms that support access to health care and other coverage required to complete key phases of the transplant evaluation process Ensure accountability and reduce interpersonal explicit or implicit biases ³⁵ that may interfere with evaluation Ensure clarity, equity, and transparency regarding the criteria for psychosocial factors used to evaluate candidates
Financial evaluation	Promote equity-focused policies and reforms Promote transparency and consistency in financial needs assessments	A patient with unstable employment benefits may lack financial resources to complete evaluation despite strong interest and need for transplant	Ensure financial counselors are trained in equity, antiracist, and unbiased principles Promote insurance and health care reforms that support transplant including the following: Advocate for employment and insurance protection for donors Implement center-level financial assistance programs that may mitigate transplant barriers Financially incentivize centers with best practices for enhancing equity Partner with community organizations that serve marginalized communities to increase access to evaluation
Social support	Promote structural competency in determining adequate social support	Patients with multiple supportive family members who have significant employment demands may not meet narrowly defined criteria for social support defined by centers	Demonstrate flexibility in the determination of social support based on the needs and availability of individuals within patients' social network Ensure antiracist, antiracist education for all transplant personnel evaluating candidates Partner with community organizations and other key partners in a social network Incentivize centers that enhance social support for providers
Adherence	Promote structural competency when considering adherence Ensure key equity criteria are consistently applied across all potential transplant candidates	Patients with significant financial concerns and limited transport options may have difficulty adhering to appointment times and evaluation requirements (eg, echocardiography)	Support policy reform that supports adherence to evaluation requirements (eg, parking vouchers, transportation, financial assistance for consultations and imaging) Promote structural competency and antiracist, unbiased education among all transplant staff

Abbreviation: QoL, quality of life; LDKT, living donor kidney transplants; SGLT2, sodium-glucose cotransporter-2 inhibitors.